How should I write a prescription for Engerix‑B (hepatitis B vaccine, recombinant) 20 µg/1 mL for a hepatitis‑naïve adult requiring the three‑dose series?

How to Write a Prescription for Engerix-B 20 µg/1.0 mL for Hepatitis-Naïve Adults

For a hepatitis-naïve adult requiring the standard three-dose series, prescribe Engerix-B 20 µg/1.0 mL intramuscularly in the deltoid muscle at 0,1, and 6 months. 1, 2

Standard Prescription Format

Write the prescription as follows:

Engerix-B (hepatitis B vaccine, recombinant) 20 µg/1.0 mL

• Route: Intramuscular (deltoid muscle)
• Schedule: Administer dose #1 today (month 0), dose #2 at 1 month, dose #3 at 6 months
• Quantity: Dispense 3 single-dose vials or prefilled syringes
• Instructions: Administer entire 1.0 mL intramuscularly into deltoid muscle per standard vaccination protocol

1, 2, 3

Critical Dosing Details

• Adults ≥20 years require 20 µg (1.0 mL) per dose on the standard 0,1,6-month schedule, achieving >90% seroprotection in healthy adults under 40 years. 1, 2, 3

• The deltoid muscle is mandatory for adults—never inject into the buttock, as this markedly reduces immunogenicity and vaccine effectiveness. 2

• Each dose must be the full 1.0 mL volume containing 20 µg of hepatitis B surface antigen. 1, 3

Minimum Interval Requirements

• Dose 1 to Dose 2: Minimum 4 weeks (28 days) 1, 2, 4

• Dose 2 to Dose 3: Minimum 8 weeks 1, 2, 4

• Dose 1 to Dose 3: Minimum 16 weeks 1, 2, 4

• Grace period: Doses given ≤4 days before the minimum interval are considered valid. 1, 2, 4

• No maximum interval exists—if the series is interrupted, simply continue where you left off; never restart the series. 2, 4

Alternative Schedules (When Standard Schedule Is Not Feasible)

• Alternative 3-dose schedules of 0,1,4 months or 0,2,4 months produce similar seroprotection rates to the standard 0,1,6-month schedule and may be used when ensuring follow-up is difficult. 2, 4

• Accelerated 4-dose schedule (0,1,2,12 months) can be used when rapid protection is needed, but the fourth dose at 12 months is essential for long-term immunity. 2, 4

• For combined hepatitis A and B protection, use Twinrix 20 µg/1.0 mL at 0,1,6 months (standard) or 0,7,21–30 days plus 12 months (accelerated). 1, 2, 5

Special Populations Requiring Different Dosing

Hemodialysis and Immunocompromised Patients

• Adults ≥20 years on hemodialysis require 40 µg (2.0 mL) administered as two simultaneous 1.0 mL injections at one site, on a 4-dose schedule at 0,1,2, and 6 months. 1, 2, 4

• Standard adult doses (20 µg) are insufficient in dialysis patients, yielding only ~50% seroprotection versus 67% with the 40 µg regimen. 2, 3

• Post-vaccination anti-HBs testing is mandatory 1–2 months after series completion to confirm protective levels (≥10 mIU/mL), with annual monitoring thereafter. 2, 4

Pregnant Women

• Pregnant women should receive only Engerix-B, Recombivax HB, or Twinrix—never use Heplisav-B or PreHevbrio due to insufficient pregnancy safety data. 2, 4

• Use the standard 0,1,6-month schedule with 20 µg (1.0 mL) per dose. 2, 4

Managing Interrupted Series

• Never restart the series regardless of time elapsed between doses. 2, 4

• If interrupted after dose 1, give dose 2 as soon as possible, then dose 3 at least 8 weeks after dose 2 and at least 16 weeks after dose 1. 2, 4

• If only dose 3 is delayed, administer it immediately upon the patient's return without waiting for a specific interval. 2, 4

• Switching vaccine brands within a series is permissible and does not require restarting. 4

Post-Vaccination Testing

• Routine serologic testing is NOT required for healthy immunocompetent adults and should not delay vaccination. 2, 4

• Mandatory anti-HBs testing 1–2 months after series completion is required for healthcare workers, public safety workers with blood exposure risk, hemodialysis patients, and immunocompromised individuals. 2, 4

• A protective level is defined as anti-HBs ≥10 mIU/mL. 2, 4, 6

Expected Immunogenicity

• After the standard 3-dose series, >90% of healthy adults <40 years achieve protective antibody levels, with a geometric mean titer of 2,204 mIU/mL at month 7. 3, 7

• Response rates decline with age—by age 60, only 75% achieve protective levels even after completing the full series. 4, 3

• Vaccine-induced immunity persists for >30 years in immunocompetent individuals. 1, 2

Common Prescribing Pitfalls to Avoid

• Never use the pediatric formulation (10 µg/0.5 mL) in adults ≥20 years—this is an inadequate dose that must be repeated with the correct 20 µg adult formulation. 2, 4

• Never inject into the buttock in adults—this substantially lowers immunogenicity and is a major cause of vaccine failure. 2

• Never restart an interrupted series—this wastes doses and delays protection. 2, 4

• Never give the third dose before 16 weeks from the first dose, even if 8 weeks have passed since the second dose. 1, 2

• Never use standard adult doses (20 µg) in hemodialysis patients—they require the 40 µg high-dose regimen. 1, 2, 4

• Never use Heplisav-B or PreHevbrio in pregnant women, hemodialysis patients, or children due to insufficient safety data. 2, 4

Documentation Requirements

• Document the vaccine lot number, expiration date, administration site (deltoid), date given, and the scheduled dates for subsequent doses. 2

• For healthcare workers and high-risk populations, document the plan for post-vaccination serologic testing 1–2 months after the final dose. 2, 4